<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892163</url>
  </required_header>
  <id_info>
    <org_study_id>SIVS1007</org_study_id>
    <nct_id>NCT01892163</nct_id>
  </id_info>
  <brief_title>Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone</brief_title>
  <acronym>OZDRY</acronym>
  <official_title>A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 μg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Royal Wolverhampton Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frimley Park Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Moorfields Eye Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg
      Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical
      coherence tomography (OCT)-guided PRN dosing in patients with refractory diabetic macular
      edema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference Between Arms in Change From Baseline Composite Scores of the National Eye Institute Visual Function Questionnaire (VFQ-25).</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>NEI VFQ 25 is a questionnaire intended to measure visual function and quality of life. It has 25 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (lowest) to 100 (highest).
Composite score = (Score for each item with a non-missing answer) / Total number of items with non-missing answers 100 = Best, 0 = Worst possible score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Arms in Change in Central Subfield Thickness.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Central subfield thickness is defined as the average thickness in the central 1mm diameter circle of the ETDRS grid and is measured in microns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Ocular and Systemic Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex PRN dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ozurdex PRN dosing versus Ozurdex fixed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozurdex fixed dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Dexamethasone implant (Ozurdex)</description>
    <arm_group_label>Ozurdex PRN dosing</arm_group_label>
    <arm_group_label>Ozurdex fixed dosing</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex aged 18 years or over

          2. Diagnosis of diabetes mellitus (type 1 or type 2).

          3. Best corrected visual acuity in the study eye between ≥34 and ≤73 ETDRS letters at 1m
             at baseline attributable to diabetic macular edema (DME)

          4. On clinical exam at baseline in the study eye, retinal thickening due to diabetic
             macular oedema involving the centre of the macula and OCT central subfield &gt; 300
             microns despite previous therapy.

          5. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate
             fundus photographs.

          6. Ability to return for study visits

          7. Visual acuity in fellow eye ≥ 2/60

          8. Ability to give informed consent throughout the duration of the study

        Main Exclusion Criteria:

          1. Macular ischaemia

          2. Macular oedema is considered to be due to a cause other than diabetic macular oedema.

          3. Co-existent ocular disease

          4. An ocular condition is present (other than diabetes) that, in the opinion of the
             investigator, might affect macular oedema or alter visual acuity during the course of
             the study.

          5. A substantial cataract that, in the opinion of the investigator, is likely to be
             decreasing visual acuity by 3 lines or more.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sobha Sivaprasad, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <results_first_submitted>September 13, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Moorfields Eye Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Sobha Sivaprasad</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Diabetic macular edema, Ozurdex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ozurdex PRN Dosing</title>
          <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
        <group group_id="P2">
          <title>Ozurdex Fixed Dosing</title>
          <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ozurdex PRN Dosing</title>
          <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
        <group group_id="B2">
          <title>Ozurdex Fixed Dosing</title>
          <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="9.8"/>
                    <measurement group_id="B2" value="63.8" spread="11.1"/>
                    <measurement group_id="B3" value="64.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months</title>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Intention to treat analysis (available case)</population>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex PRN Dosing</title>
            <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
          <group group_id="O2">
            <title>Ozurdex Fixed Dosing</title>
            <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months</title>
          <population>Intention to treat analysis (available case)</population>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="13.0"/>
                    <measurement group_id="O2" value="0.53" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Arms in Change From Baseline Composite Scores of the National Eye Institute Visual Function Questionnaire (VFQ-25).</title>
        <description>NEI VFQ 25 is a questionnaire intended to measure visual function and quality of life. It has 25 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (lowest) to 100 (highest).
Composite score = (Score for each item with a non-missing answer) / Total number of items with non-missing answers 100 = Best, 0 = Worst possible score</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Though 48 patients completed the trial in the PRN arm, one patient did not complete the questionnaire completely, making it invalid for analysis. Hence the PRN arm number for this outcome was 47</population>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex PRN Dosing</title>
            <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
          <group group_id="O2">
            <title>Ozurdex Fixed Dosing</title>
            <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Arms in Change From Baseline Composite Scores of the National Eye Institute Visual Function Questionnaire (VFQ-25).</title>
          <description>NEI VFQ 25 is a questionnaire intended to measure visual function and quality of life. It has 25 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (lowest) to 100 (highest).
Composite score = (Score for each item with a non-missing answer) / Total number of items with non-missing answers 100 = Best, 0 = Worst possible score</description>
          <population>Though 48 patients completed the trial in the PRN arm, one patient did not complete the questionnaire completely, making it invalid for analysis. Hence the PRN arm number for this outcome was 47</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="12.2"/>
                    <measurement group_id="O2" value="3.02" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Arms in Change in Central Subfield Thickness.</title>
        <description>Central subfield thickness is defined as the average thickness in the central 1mm diameter circle of the ETDRS grid and is measured in microns</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Few patients in both groups developed cataract. Due to the dense cataract, it was not possible to obtain the macular scans. Hence the discrepancy between the population who completed the study and the number for whom the OCT was obtained at exit visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex PRN Dosing</title>
            <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
          <group group_id="O2">
            <title>Ozurdex Fixed Dosing</title>
            <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Arms in Change in Central Subfield Thickness.</title>
          <description>Central subfield thickness is defined as the average thickness in the central 1mm diameter circle of the ETDRS grid and is measured in microns</description>
          <population>Few patients in both groups developed cataract. Due to the dense cataract, it was not possible to obtain the macular scans. Hence the discrepancy between the population who completed the study and the number for whom the OCT was obtained at exit visit.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.1" spread="96.2"/>
                    <measurement group_id="O2" value="-179.9" spread="172.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Ocular and Systemic Serious Adverse Events</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex PRN Dosing</title>
            <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
          <group group_id="O2">
            <title>Ozurdex Fixed Dosing</title>
            <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Ocular and Systemic Serious Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year (between baseline and exit)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ozurdex PRN Dosing</title>
          <description>Ozurdex PRN dosing versus Ozurdex fixed dosing
Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
        <group group_id="E2">
          <title>Ozurdex Fixed Dosing</title>
          <description>Ozurdex: Dexamethasone implant (Ozurdex)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>other non ocular events</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>cataract surgery in study eye</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Other non specific eye problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Raised Intraocular Pressure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>cataract progresion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Sobha Sivaprasad</name_or_title>
      <organization>Moorfields Eye Hospital NHS Foundation Trust</organization>
      <phone>02072533411</phone>
      <email>sobha.sivaprasad@moorfields.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

